>
Switch to:

NovoCure Days Payable

: 176.41 (As of Sep. 2021)
View and export this data going back to 2015. Start your Free Trial

NovoCure's average Accounts Payable for the three months ended in Sep. 2021 was $58.4 Mil. NovoCure's Cost of Goods Sold for the three months ended in Sep. 2021 was $30.2 Mil. Hence, NovoCure's Days Payable for the three months ended in Sep. 2021 was 176.41.

The historical rank and industry rank for NovoCure's Days Payable or its related term are showing as below:

NAS:NVCR' s Days Payable Range Over the Past 10 Years
Min: 100.12   Med: 146.83   Max: 535.35
Current: 170.93

100.12
535.35

During the past 8 years, NovoCure's highest Days Payable was 535.35. The lowest was 100.12. And the median was 146.83.

NAS:NVCR's Days Payable is ranked higher than
79% of the 713 Companies
in the Medical Devices & Instruments industry.

( Industry Median: 66.91 vs. NAS:NVCR: 170.93 )

NovoCure's Days Payable increased from Sep. 2020 (129.69) to Sep. 2021 (176.41). It may suggest that NovoCure delayed paying its suppliers.


NovoCure Days Payable Historical Data

The historical data trend for NovoCure's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Days Payable
Premium Member Only Premium Member Only Premium Member Only 138.45 116.71 100.12 131.06 155.20

NovoCure Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Days Payable Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.69 155.43 183.90 174.67 176.41

Competitive Comparison

For the Medical Instruments & Supplies subindustry, NovoCure's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

NovoCure Days Payable Distribution

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Days Payable distribution charts can be found below:

* The bar in red indicates where NovoCure's Days Payable falls into.



NovoCure Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

NovoCure's Days Payable for the fiscal year that ended in Dec. 2020 is calculated as

Days Payable (A: Dec. 2020 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2019 ) + Accounts Payable (A: Dec. 2020 )) / count ) / Cost of Goods Sold (A: Dec. 2020 )*Days in Period
=( (36.925 + 53.647) / 2 ) / 106.501*365
=45.286 / 106.501*365
=155.20

NovoCure's Days Payable for the quarter that ended in Sep. 2021 is calculated as:

Days Payable (Q: Sep. 2021 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2021 ) + Accounts Payable (Q: Sep. 2021 )) / count ) / Cost of Goods Sold (Q: Sep. 2021 )*Days in Period
=( (56.785 + 60.005) / 2 ) / 30.206*365 / 4
=58.395 / 30.206*365 / 4
=176.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovoCure Days Payable Related Terms

Thank you for viewing the detailed overview of NovoCure's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure Business Description

NovoCure logo
Industry
Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, Saint Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.
Executives
Weinberg Uri officer: Chief Science Officer NOVOCURE INC., 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355
Groenhuysen Wilhelmus Cm officer: Chief Operating Officer C/O NAVTEQ CORPORATION 222 MERCHANDISE MART STE 900 CHICAGO IL 60654
Danziger Asaf director, officer: Chief Executive Officer 5 NACHUM CHAT ST. TIRAT HACARMEL L3 5112302
Leung Gabriel director C/O PERNIX THERAPEUTICS HOLDINGS, INC. 10 NORTH PARK PLACE, SUITE 201 MORRISTOWN NJ 07960
Shah Pritesh officer: Chief Commercial Officer C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Leonard Frank X officer: Chief Development Officer 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Cordova Ashley officer: Chief Financial Officer 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Madden Martin J. director C/O MICROBOT MEDICAL INC. 175 DERBY STREET 27/1 HINGHAM MA 02043
Benaim Ely officer: Chief Medical Officer C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850
Doyle William F director, officer: Executive Chairman PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DOYLE WILLIAM F a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Ambrogi Michael J. officer: Chief Operating Officer 195 COMMERCE WAY PORTSMOUTH NH 03801
Longsworth Todd Christopher officer: General Counsel NOVOCURE, 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355
Hilleman Jeryl L director C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mccoy Sherilyn S director JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Hung David director C/O AXOVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018

NovoCure Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)